← Leaderboards
Wen-Hsuan Chang
Acurastem, Inc.
$2,212,802
Attributed
$4,425,603
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2021–24$2M$1.5M$1M$500K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$4,425,603 · 3
By mechanism
R44$4,425,603 · 3
Top collaborators
- Samuel V Alworth5 shared
- Zhihua Feng1 shared
Most similar at Acurastem, Inc.
Same institution · by research overlap
- Samuel V Alworth$4,714,159
- Zhihua Feng$2,782,758
- Hongyan Zhou$1,581,576
- Qing Liu-Michael$112,468
Others in their field
Other Emerging Leaders on “Genetic”
- Leonard Freedman · Leidos Biomedical Research, Inc.$89,060,933
- Ted Ross · University Of Georgia$68,763,143
- Scott Topper · Broad Institute, Inc.$64,989,588
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$56,084,949
- Yunda Huang · Fred Hutchinson Cancer Center$51,342,169
- Dale Sandler · Social And Scientific Systems, Inc.$43,209,852
Research focus
GeneticAntisense OligonucleotidesToxic EffectSafetyAutomobile DrivingSmall MoleculeGenesNeuronsPhosphotransferasesPharmaceutical PreparationsMediatingAutophagocytosisFrontotemporal DementiaLeadNew Therapeutic TargetIn VitroComplexKnock-DownProtein Tdp-43Dna Sequence AlterationC9orf72Nerve DegenerationGenetic Predisposition To DiseaseNovel Therapeutic Intervention
Grant awards (6)
Development of an UNC13A antisense oligonucleotide treatment for ALS and FTD$1,279,990
R44 · FY2024 · NS · contact PI
Development of a PIKFYVE antisense oligonucleotide treatment for FTD$1,480,550
R44 · FY2022 · NS
Development of a PIKFYVE antisense oligonucleotide treatment for FTD$76,492
R44 · FY2022 · NS
Development of a PIKFYVE Antisense Oligonucleotide Treatment for FTD$40,846
R44 · FY2022 · NS
Development of a PIKFYVE antisense oligonucleotide treatment for FTD$1,014,266
R44 · FY2021 · NS
PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD$533,459
R44 · FY2021 · NS